Somya Sugandha joins Thermo Fisher Scientific as Vice President – HR, APMEA
Somya Sugandha has been appointed Vice President – Human Resources for the APMEA region at Thermo Fisher Scientific, bringing over 25 years of diverse HR experience. Previously, she spent nearly 14 years with Alstom, General Electric, and GE Vernova, where she significantly contributed to cultural transformation and employee experience. In her new role, she will align the people strategy with Thermo Fisher Scientific's mission to impact lives through science and innovation.
How Thermo Fisher’s Glacios 3 aims to broaden access to cryo-EM
Thermo Fisher Scientific has introduced the Glacios 3 Cryo-TEM, a 200 kV cryo-electron microscope designed to overcome the historical challenges of bringing cryo-EM technology in-house for biotech and pharmaceutical companies. This new system, featuring a built-in environmental mitigation package (READY System) and AI-powered software, aims to simplify installation, reduce facility renovation needs, and make the technology more accessible and user-friendly. By streamlining operations and shortening the feedback loop on data quality, the Glacios 3 seeks to enable researchers to focus more on biological insights and accelerate structure-based drug design.
Encompass Health Corp Stock (EHC) Moved Up by 7.51% on Apr 6: What Signal Does It Send?
Encompass Health Corp (EHC) saw its stock rise by 7.51% on April 6, driven by a proposed increase in payment rates for rehabilitation hospitals by CMS and positive "Overweight" ratings from analysts like KeyBanc and Barclays. This upward movement occurred despite a recent securities fraud investigation, suggesting the market prioritized the favorable regulatory and analyst news. The company's strong Q4 2025 results also provided a positive financial foundation.
Biodesix Announces AACR 2026 Posters and Presentations
Biodesix, Inc. will present seven abstracts, including two oral sessions, at the American Association for Cancer Research (AACR) Annual Meeting in San Diego, CA, from April 17 - 22, 2026. The presentations highlight the company's expertise in blood- and tissue-based testing, covering novel proteomic and genomic approaches for oncology therapeutic selection, response monitoring, and Molecular Residual Disease (MRD) testing. This demonstrates Biodesix's comprehensive capabilities from basic research to clinical applications and pre-validated assays for partners, alongside advancements in their pipeline.
Cancer test developer Biodesix brings 7 studies to AACR meeting
Biodesix (Nasdaq: BDSX) announced it will present seven abstracts, including two oral sessions, at the AACR Annual Meeting in San Diego from April 17–22, 2026. The presentations will cover various aspects of cancer diagnostics, including blood- and tissue-based testing, tumor and immune profiling, and multi-omic molecular residual disease (MRD) pipeline development. This includes novel proteomic and genomic approaches leveraging technologies like mass spectrometry, Bio-Rad ddPCR, and Thermo Fisher Ion AmpliSeq and Ion Torrent Genexus workflows, with collaborators such as Memorial Sloan Kettering Cancer Center co-presenting data.
Biodesix to Showcase Advances in Diagnostic Solutions at AACR Annual Meeting 2026
Biodesix, Inc. will present seven abstracts, including two oral sessions, at the AACR Annual Meeting from April 17-22, 2026, in San Diego. The presentations will highlight the company's expertise in blood- and tissue-based diagnostic testing for cancer, focusing on advancements in genomic and proteomic technologies, tumor and immune profiling, and molecular residual disease monitoring. This includes the validation of a new clinical myeloid panel capable of delivering rapid sequencing results.
Thermo Fisher Introduces Gibco CTS Compleo Fill and Finish System
Thermo Fisher Scientific has launched the Gibco CTS Compleo Fill and Finish System, an automated and functionally closed system designed to enhance cell therapy manufacturing. This system aims to streamline formulation and filling processes, reduce manual intervention, and improve consistency, addressing a significant bottleneck in the production of cell therapies. It is part of the Gibco Cell Therapy Systems portfolio, which provides integrated solutions to support GMP-compliant manufacturing.
Blood Viscometer Market Is Going to Boom |• Thermo Fisher Scientific • Brookfield Engineering
Worldwide Market Reports has released a comprehensive research study titled "Blood Viscometer Market Size and Forecast 2026-2033," analyzing the market's expected growth using primary and secondary research methodologies. The report details key market drivers, challenges, opportunities, and restraints, and includes a competitive landscape overview with profiles of major players like Thermo Fisher Scientific and Brookfield Engineering. It segments the market by types and applications, provides a geographical analysis, and offers key insights for stakeholders and investors.
Genome Editing Market Is Going to Boom |• CRISPR Therapeutics • Editas Medicine
Worldwide Market Reports has published a comprehensive analysis titled "Genome Editing Market Size and Forecast 2026-2033," predicting significant growth in the genome editing sector. The report, based on extensive research, details market drivers, challenges, opportunities, and competitive landscapes, featuring key players like CRISPR Therapeutics and Editas Medicine. It offers crucial insights for stakeholders, covering market segmentation by types and applications, regional trends, and forecasts to aid investment decisions.
Electron Microscopes Market Is Going to Boom |• Thermo Fisher Scientific • JEOL Ltd.
Worldwide Market Reports has released a comprehensive research study on the Electron Microscopes Market, forecasting its growth from 2026 to 2033. The report, developed using primary and secondary research, details market size, competitive landscape, key players like Thermo Fisher Scientific and JEOL Ltd., and segmentation by type and application. It also provides insights into regional trends, growth drivers, challenges, and opportunities for stakeholders.
Thermo Fisher Microscopes: Precision in Scientific Imaging
This article details how Thermo Fisher microscopes are crucial for scientific imaging across various research and industrial applications. It highlights their advanced optical and electron models, cutting-edge features like high-resolution optics, fluorescence capabilities, and automation. The article also discusses their market relevance, competitive landscape, ongoing innovations, and significant impact on global health and scientific discovery.
JB Capital LLC Decreases Position in Thermo Fisher Scientific Inc. $TMO
JB Capital LLC significantly decreased its stake in Thermo Fisher Scientific Inc. during the fourth quarter, selling 4,791 shares and retaining 6,672 shares valued at $3.87 million. Despite this, Thermo Fisher Scientific reported strong Q4 results, surpassing earnings and revenue expectations, and increased its quarterly dividend. Analysts maintain a "Moderate Buy" rating for the stock, with institutional investors holding a large majority of shares.
Stocks to Avoid Under $10: iHeartMedia, Energy Recovery, Neogen Analysis | 2026 - News and Statistics
StockStory identifies three specific stocks priced under $10 to avoid in 2026: iHeartMedia (IHRT), Energy Recovery (ERII), and Neogen (NEOG). The firm cautions investors about the speculative nature of low-priced stocks and points out factors like below-sector revenue growth, diminishing returns on capital, and dilution risks for these companies. The article provides a brief analysis of each company's financial health and market position.
Perpetual Ltd Has $157.65 Million Stock Holdings in Thermo Fisher Scientific Inc. $TMO
Perpetual Ltd recently decreased its holdings in Thermo Fisher Scientific Inc. (TMO) by 35.1%, now owning 272,061 shares valued at approximately $157.65 million. This makes TMO its 11th-largest holding. Meanwhile, Thermo Fisher Scientific surpassed quarterly earnings expectations, increased its dividend, and maintains a "Moderate Buy" consensus rating from analysts.
Danaher Corporation (1DHR.MI) stock price, news, quote and history
This page provides comprehensive information on Danaher Corporation (1DHR.MI), including its stock price, news, quotes, and historical data. It offers an overview of the company's operations across Biotechnology, Life Sciences, and Diagnostics segments, along with key financial statistics, performance metrics, and comparison tools with similar companies.
Thermo Fisher Scientific Introduces the Gibco™ CTS™ Compleo™ Fill and Finish System to Help Streamline Cell Therapy Manufacturing
Thermo Fisher Scientific has launched the Gibco™ CTS™ Compleo™ Fill and Finish System, an automated, functionally closed solution designed to streamline formulation and filling in cell therapy manufacturing. This system aims to reduce manual intervention, improve consistency, and address variability challenges in cell therapy production, which traditionally relies on manual methods. Early collaborators, such as Arsenal Biosciences, have reported positive results in using the system to enhance scalability and automation in their cell therapy programs.
Assessing Thermo Fisher Scientific (TMO) Valuation After Recent Biotech Tools And Cryo TEM Launches
Thermo Fisher Scientific (TMO) has recently launched several new biotech tools and cell therapy products. Despite these new offerings, the stock's recent share price returns show fading momentum, though analysts suggest it is currently undervalued by about 9% compared to a narrative-driven fair value of $540.27. The narrative emphasizes resilient demand, a recurring revenue model, and expectations of steady top-line growth and improved margins.
Marc Casper: Scientific Instruments Visionary, Thermo Fisher Scientific Chairman and CEO, and Architect of Life Sciences Excellence
Marc Casper, the Chairman and CEO of Thermo Fisher Scientific, has transformed the company into a leader in life sciences and scientific instruments. Since becoming CEO in 2009, he has quadrupled revenues to over $40 billion through strategic acquisitions and a focus on customer needs and operational excellence. Casper's leadership was particularly evident during the COVID-19 pandemic, where Thermo Fisher Scientific played a crucial role in diagnostic testing and vaccine manufacturing support.
Thermo Fisher Scientific introduces Gibco™ CTS™ Compleo™ Fill and Finish System
Thermo Fisher Scientific has launched the Gibco™ CTS™ Compleo™ Fill and Finish System to automate and streamline the formulation and filling processes in cell therapy manufacturing. This functionally closed solution aims to reduce manual intervention and enhance consistency in manufacturing outcomes, addressing variability often encountered with patient-derived cell therapies. The system is designed to improve operational efficiency and maintain sterility, dose accuracy, and product consistency as cell therapies progress towards commercialization.
Neogen Leadership Change Puts Governance And Compliance Execution In Focus
Neogen (NasdaqGS:NEOG) has announced the departure of its Chief Legal and Administrative Officer, Amy Rocklin, effective March 31, 2026. This leadership change is significant due to Neogen's recent performance fluctuations and ongoing issues like labor actions and product quality concerns. Investors are advised to monitor the company's succession plan, shifts in compliance priorities, and how the board communicates around this transition, especially given the company's current unprofitability and integration challenges.
Aberdeen Group plc Grows Stock Holdings in Thermo Fisher Scientific Inc. $TMO
Aberdeen Group plc increased its stake in Thermo Fisher Scientific Inc. by 1.6% in the fourth quarter, bringing its total ownership to 383,832 shares valued at $222.4 million. Other institutional investors also adjusted their positions, and analysts generally maintain a "Moderate Buy" rating for TMO, with a consensus target price of $632.50. The company recently reported strong quarterly earnings, exceeding analyst expectations, and increased its quarterly dividend.
36Kr Exclusive: Ex-Thermo Fisher Employee Launches Lights-Out Lab with 100% Domestic Delivery, Secures Nearly $100M in Financing
Daina Technology, founded by ex-Thermo Fisher employee Chi Haipeng, recently secured nearly 100 million yuan in Series B+ financing to expand its "lights-out laboratory" technology. The company specializes in AI-driven, fully unmanned, and closed-loop laboratories for scientific research, achieving 100% domestic delivery success. Daina Technology plans to further develop its AI infrastructure for science, expand its market share, and collaborate with institutions like Beijing University of Chemical Technology to accelerate AI + new materials R&D.
Lab chromatographs are getting smarter: what Agilent is quietly changing for US labs
This article discusses how Agilent Technologies Inc. and other manufacturers are transforming US labs with smarter, more automated chromatographs. These new systems enhance throughput, compliance, and uptime through automation, AI-assisted analytics, and improved data integrity, moving beyond raw performance to focus on system-level intelligence and workflow efficiency. The piece highlights the benefits for labs struggling with staffing and regulatory burdens, positioning upgrades as a workflow redesign rather than just an instrument purchase.
Takeda Pharmaceuticals to lay off 247 employees at Cambridge location
Takeda Pharmaceuticals, the largest biopharma employer in Massachusetts, announced layoffs impacting 247 employees at its Cambridge location, with an additional 387 layoffs in other states. The company cites a restructuring plan aiming for $1.3 billion in savings, while critics attribute the move to Massachusetts' unfriendly business environment due to high taxes and costs. This follows several other company departures from the state, despite the state's efforts to address housing costs contributing to outmigration.
Danaher Corp. Experiences Valuation Adjustment Amid Competitive Market Landscape
Danaher Corp., a significant player in the Pharmaceuticals & Biotechnology sector, has seen a valuation adjustment with its stock price at $190.79, reflecting a -4.79% return over the past year. The company's financial metrics include a P/E ratio of 41 and a dividend yield of 0.54%, indicating a competitive position but also challenges in growth compared to its peers like Abbott Laboratories and Thermo Fisher Scientific.
At Harvard gala, QT Imaging CEO pushes earlier breast cancer detection
QT Imaging Holdings, Inc. CEO Dr. Raluca Dinu participated in the inaugural Shiftmakers Gala at Harvard University, highlighting the importance of early breast cancer detection. Dinu emphasized that their radiation-free imaging technology addresses the challenge of dense breast tissue, which often makes mammography alone insufficient for many women. The event, supported by Gloria Steinem, focused on women driving change, and QT Imaging's work will be featured in The Shift to further promote awareness.
Thermo Fisher Scientific Introduces the Gibco™ CTS™ Compleo™ Fill and Finish System to Help Streamline Cell Therapy Manufacturing
Thermo Fisher Scientific has launched the Gibco™ CTS™ Compleo™ Fill and Finish System, an automated and functionally closed solution designed to streamline cell therapy manufacturing. This system addresses challenges in manual formulation and filling workflows, aiming to reduce risk, improve operational efficiency, and ensure product consistency. It is part of the larger Gibco™ Cell Therapy Systems™ portfolio, providing integrated solutions for Good Manufacturing Practice (GMP)-compliant, closed-system cell therapy manufacturing.
Thermo Fisher Scientific Introduces the Gibco™ CTS™ Compleo™ Fill and Finish System to Help Streamline Cell Therapy Manufacturing
Thermo Fisher Scientific has launched the Gibco™ CTS™ Compleo™ Fill and Finish System, an automated and functionally closed solution designed to streamline the formulation and filling processes in cell therapy manufacturing. This system aims to reduce manual intervention, address cell variability, and improve operational efficiency and consistency, which are critical challenges as cell therapies move toward commercialization. Early collaborators have reported benefits in reducing variability and streamlining manufacturing processes with this new technology.
Thermo Fisher Scientific Introduces the Gibco™ CTS™ Compleo™ Fill and Finish System to Help Streamline Cell Therapy Manufacturing
Thermo Fisher Scientific has launched the Gibco™ CTS™ Compleo™ Fill and Finish System, an automated and functionally closed solution designed to streamline cell therapy manufacturing. This system addresses common challenges in manual formulation and filling by reducing manual intervention and improving consistency. Collaborators using the technology are already seeing benefits in advancing their cell therapy programs.
In 211 myeloma samples, OGM found abnormalities older tests missed
Bionano (Nasdaq: BNGO) announced a multicenter study published in April 2026, demonstrating that optical genome mapping (OGM) outperforms traditional cytogenetic methods in analyzing multiple myeloma (MM) samples. The study, involving 211 MM samples, found that OGM identified relevant abnormalities in 92% of cases previously deemed normal by karyotype and resolved 82% of samples that failed karyotyping, also detecting complex events like chromoanagenesis in ~29% of samples. This suggests OGM can provide a more comprehensive view of genomic alterations and addresses medical society recommendations for MM analysis, potentially driving increased adoption and utilization of OGM.
Exosomes Market Evolution (2026) | Nano Vesicles, Liquid Biopsy, Oncology Research & Biotech Investments | Top Companies 2026 - Miltenyi Biotec, Novus Biologicals, Capital Biosciences, and Bio Techne
DataM Intelligence has released a new research report on the Exosomes Market, highlighting its projected growth between 2026 and 2033. The report offers in-depth insights into market dynamics, segmentation, and includes recent industry developments and mergers & acquisitions. Key players listed include Thermo Fisher Scientific Inc., Qiagen, Beckman Coulter, Inc., and Lonza, among others, with the market focusing on oncology, neurodegenerative diseases, and regenerative medicine applications.
TMO Stock May Gain From the Rollout of Gibco CHOvantage GS CLD Kit
Thermo Fisher Scientific (TMO) has introduced its new Gibco CHOvantage GS Cell Line Development Kit, designed to accelerate biologics development and improve cell line productivity. This innovation is expected to boost TMO's cell culture business and stock performance, as the biologics market continues to expand due to increasing chronic diseases and demand for efficient therapeutic development. The company’s stock rose 0.6% after the announcement, and analysts predict a positive impact on its future performance.
AAV Genome Sequencing Service Market Is Booming Rapidly with Strong Demand By 2033 | Thermo Fisher Scientific, Illumina, Danaher Corporation
Coherent Market Insights has published a new research study on the Global "AAV Genome Sequencing Service Market" forecasting growth through 2033. The report segments the market by type, application, end-user, and region, identifying key players like Thermo Fisher Scientific, Illumina, and Danaher Corporation. It aims to provide a comprehensive analysis of market trends, drivers, restraints, competitive landscape, and regional dynamics to aid strategic decision-making.
Agilent Announces the BioTek Cytation 9 Cell Imaging Multimode Reader
Agilent Technologies has launched the BioTek Cytation 9 cell imaging multimode reader, enhancing its Cytation portfolio. This new instrument combines multimode microplate reading and high-content cell imaging, offering expanded capabilities and faster throughput for diverse research applications. Designed with customer feedback, it aims to accelerate discoveries in cell biology and drug development by streamlining workflows for both cell-based and biochemical assays.
Thermo Fisher Scientific to Hold Earnings Conference Call on Thursday, April 23, 2026
Thermo Fisher Scientific Inc. announced it will release its first-quarter 2026 financial results before market open on Thursday, April 23, 2026. The company will hold a conference call the same day at 8:30 a.m. ET to discuss its financial performance and future expectations. The call will be webcast live on their website and accessible by phone.
Compagnie Lombard Odier SCmA Buys 5,895 Shares of Thermo Fisher Scientific Inc. $TMO
Compagnie Lombard Odier SCmA increased its stake in Thermo Fisher Scientific Inc. by 2.0%, acquiring an additional 5,895 shares, bringing its total holdings to 299,655 shares valued at $173.64 million. Thermo Fisher Scientific recently reported strong quarterly results with $6.57 EPS and $12.22 billion in revenue, also raising its quarterly dividend. Despite some insider selling, analysts maintain a "Moderate Buy" rating with an average price target of $632.50.
Exosome Research Market is Thriving Worldwide | Thermo Fisher Scientific, Illumina Inc, Miltenyi Biotec, QIAGEN
The Exosome Research Market is projected to grow from USD 284.5 million in 2026 to USD 895.5 million by 2033, exhibiting a compound annual growth rate of 17.8%. This growth is driven by increasing industry demand, expanding applications, and technological advancements. The report, by Coherent Market Insights, provides a detailed analysis of market size, revenue trends, key growth factors, competitive landscape, and strategic opportunities for stakeholders.
Quantum-Si (NASDAQ: QSI) plans 2026 virtual meeting and pay vote
Quantum-Si (NASDAQ: QSI) will hold its fully virtual 2026 annual shareholder meeting on May 15, 2026, at 1:00 p.m. Eastern, where stockholders will vote on electing ten directors, ratifying PricewaterhouseCoopers LLP as auditor, and approving a non-binding advisory say-on-pay for named executive officers. Founder Jonathan M. Rothberg, Ph.D., who beneficially owns all Class B shares, holds approximately 69.33% of the total voting power, effectively controlling the outcome of all proposals. The proxy statement details executive compensation for 2025, outstanding equity awards, and director compensation.
Equity plan expansion at DiaMedica (NASDAQ: DMAC) adds 3.5M shares
DiaMedica Therapeutics Inc. (NASDAQ: DMAC) is proposing to expand its 2019 Omnibus Incentive Plan by adding 3.5 million shares, increasing the total authorized shares to 10.5 million, and extending the plan's term by ten years. This proposal will be voted on at the annual shareholder meeting on May 20, 2026, alongside the election of directors, ratification of Baker Tilly US, LLP as auditors, and an advisory vote on executive compensation. The company states the expansion is crucial for attracting, motivating, and retaining talent and aligns with its pay-for-performance compensation philosophy.
Thermo Fisher Scientific Launches Integrated Platform to Accelerate Biologics Development
Thermo Fisher Scientific has launched an integrated platform called the Gibco CHOvantage GS Cell Line Development Kit to speed up biologics development. This new platform aims to help manufacturers bring therapies to market faster, improve consistency, and control costs, especially for complex biologics and biosimilars. The kit offers high productivity, streamlined timelines, and royalty-free, clinical-stage licensing options to support scalable manufacturing.
Thermo Fisher Scientific to Hold Earnings Conference Call on Thursday, April 23, 2026
Thermo Fisher Scientific Inc. (NYSE: TMO) announced it will release its first-quarter 2026 financial results and hold a conference call on Thursday, April 23, 2026, at 8:30 a.m. ET. The call will discuss financial performance and future expectations, accessible via webcast on their website or by phone. A replay of the call will be available until July 22, 2026.
Worldwide Factors Influencing the Rapid Evolution of the Life Science Tools Market
The life science tools market is projected to reach $379.95 billion by 2030, growing at a CAGR of 13.5%. This growth is fueled by automation, increased investments in genomics and proteomics, demand for personalized medicine, and advancements in clinical diagnostics and drug discovery. Key players like F. Hoffmann-La Roche Ltd. and Thermo Fisher Scientific Inc. are driving innovation, exemplified by strategic acquisitions and the development of advanced sequencing platforms such as Illumina's MiSeq i100 series.
SOLV SEC Filings - Solventum Corporation 10-K, 10-Q, 8-K Forms
This page provides a comprehensive resource for investors to access Solventum Corporation's SEC filings, including 10-K, 10-Q, 8-K forms, and insider trading reports. It highlights various material events reported by Solventum, such as debt reduction strategies, asset sales, governance changes, and details related to 3M Company's ownership and share resales of SOLV stock. The platform offers AI-powered summaries and sentiment analysis for each filing to help users understand key financial and operational disclosures.
Key Factors and Emerging Trends Shaping the Lab Supplies Market Landscape
The lab supplies market is set to reach $60.9 billion by 2030, growing at an 8.5% CAGR, driven by advancements in life sciences, diagnostics, and automation. Key trends include increased demand for premium consumables, automated equipment, and a focus on safety and sustainability. Leading companies like Thermo Fisher Scientific and Danaher Corporation are innovating to enhance accuracy and efficiency, with acquisitions like Calibre Scientific's purchase of Dynalab Corp. expanding market reach and product portfolios.
Smarter Raman QC for biopharma fill-finish with scalable model transfer
This webinar, sponsored by Thermo Fisher Scientific and featuring Sudhir Dahal, explores how modern Raman spectroscopy can enhance biopharma fill-finish quality control. It focuses on leveraging faster analysis and multi-attribute insights, while addressing challenges like scalable model transfer across instruments and sites, managing fluorescence interference, and integrating data into Industry 4.0 environments for real-time release. The session offers practical strategies for implementing Raman-based QC effectively in complex manufacturing operations.
Live Cell Imaging Market Set to Boom Rapidly by 2033| Thermo Fisher Scientific Inc. • Merck KgaA • PerkinElmer Inc
The Live Cell Imaging market is expected to grow significantly, from US$ 1,924.4 Mn in 2025 to US$ 2,921.9 Mn by 2032, at a CAGR of 7.2%. This report provides an in-depth analysis of market dynamics, key players such as Thermo Fisher Scientific, Merck KgaA, and PerkinElmer Inc., regional trends, and growth opportunities with forecasts up to 2033. It serves as a strategic guide for stakeholders with competitive analysis, market segmentation, and crucial insights to foster sustainable growth.
Emerging Sub-Segments Transforming the Medical Device Subscription Market Landscape
The medical device subscription market is projected to reach $24.89 billion by 2030, growing at a CAGR of 22.5%, driven by remote monitoring, AI, and telehealth integration. Key players like Thermo Fisher Scientific and Medtronic are shaping the industry, with innovations like next-generation health wearables fostering personalized wellness management. The market is segmented by device type, subscription model, application, and end-user, including diagnostic, therapeutic, and monitoring devices across various medical fields.
Thermo Fisher Scientific Launches Integrated Platform to Accelerate Biologics Development
Thermo Fisher Scientific has released an integrated cell line development platform, the Gibco™ CHOvantage™ GS Cell Line Development Kit, aimed at accelerating biologics development. This platform provides high productivity, streamlined timelines, and royalty-free, clinical-stage licensing options, addressing the growing demand for faster and more cost-effective manufacturing of protein therapeutics. The kit enables rapid generation of high-performing CHO cell lines and supports a seamless transition from development to commercial manufacturing.
Thermo Fisher Scientific Launches Integrated Platform to Accelerate Biologics Development
Thermo Fisher Scientific has introduced a new integrated cell line development platform, the Gibco CHOvantage GS Cell Line Development Kit, designed to accelerate biologics development. This platform aims to reduce time to clinic, improve manufacturing efficiency, and lower costs for protein therapeutics and biosimilars. A key feature is its royalty-free, clinical-stage licensing, offering predictability and flexibility for manufacturers.
Thermo Fisher Scientific Launches Integrated Platform to Accelerate Biologics Development
Thermo Fisher Scientific has launched a new integrated cell line development platform, the Gibco CHOvantage GS Cell Line Development Kit, designed to accelerate biologics development. This platform aims to help manufacturers bring therapies to market faster by improving productivity, streamlining timelines, and offering royalty-free clinical-stage licensing options. It integrates a transposon-based vector system with optimized media to enhance cell line productivity and process consistency from research through commercial production.
